Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

Amar Gajjar, Murali Chintagumpala, David Ashley, Stewart Kellie, Larry E. Kun, Thomas E. Merchant, Shaio Woo, Greg Wheeler, Valerie Ahern, Matthew J. Krasin, Maryam Fouladi, Alberto Broniscer, Robert Krance, Gregory A. Hale, Clinton F. Stewart, Robert Dauser, Robert A. Sanford, Christine Fuller, Ching Lau, James M. BoyettDana Wallace, Richard J. Gilbertson

Research output: Contribution to journalArticle

522 Citations (Scopus)

Abstract

Background: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. Methods: After resection, patients were classified as having average-risk medulloblastoma (≤1·5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma (>1·5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23·4 Gy for average-risk disease and 36·0-39·6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211. Findings: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89%) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85% (95% CI 75-94) in patients in the average-risk group and 70% (54-84) in those in the high-risk group (p=0·04); 5-year event-free survival was 83% (73-93) and 70% (55-85), respectively (p=0·046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0·04): 84% (74-95) for classic histology, 77% (49-100) for desmoplastic tumours, and 57% (33-80) for large-cell anaplastic tumours. Interpretation: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.

Original languageEnglish (US)
Pages (from-to)813-820
Number of pages8
JournalLancet Oncology
Volume7
Issue number10
DOIs
StatePublished - Oct 1 2006

Fingerprint

Medulloblastoma
Multicenter Studies
Radiotherapy
Stem Cells
Drug Therapy
Disease-Free Survival
Histology
Survival
Residual Neoplasm
Therapeutics
Cyclophosphamide
Neoplasms
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology

Cite this

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96) : long-term results from a prospective, multicentre trial. / Gajjar, Amar; Chintagumpala, Murali; Ashley, David; Kellie, Stewart; Kun, Larry E.; Merchant, Thomas E.; Woo, Shaio; Wheeler, Greg; Ahern, Valerie; Krasin, Matthew J.; Fouladi, Maryam; Broniscer, Alberto; Krance, Robert; Hale, Gregory A.; Stewart, Clinton F.; Dauser, Robert; Sanford, Robert A.; Fuller, Christine; Lau, Ching; Boyett, James M.; Wallace, Dana; Gilbertson, Richard J.

In: Lancet Oncology, Vol. 7, No. 10, 01.10.2006, p. 813-820.

Research output: Contribution to journalArticle

Gajjar, A, Chintagumpala, M, Ashley, D, Kellie, S, Kun, LE, Merchant, TE, Woo, S, Wheeler, G, Ahern, V, Krasin, MJ, Fouladi, M, Broniscer, A, Krance, R, Hale, GA, Stewart, CF, Dauser, R, Sanford, RA, Fuller, C, Lau, C, Boyett, JM, Wallace, D & Gilbertson, RJ 2006, 'Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial', Lancet Oncology, vol. 7, no. 10, pp. 813-820. https://doi.org/10.1016/S1470-2045(06)70867-1
Gajjar, Amar ; Chintagumpala, Murali ; Ashley, David ; Kellie, Stewart ; Kun, Larry E. ; Merchant, Thomas E. ; Woo, Shaio ; Wheeler, Greg ; Ahern, Valerie ; Krasin, Matthew J. ; Fouladi, Maryam ; Broniscer, Alberto ; Krance, Robert ; Hale, Gregory A. ; Stewart, Clinton F. ; Dauser, Robert ; Sanford, Robert A. ; Fuller, Christine ; Lau, Ching ; Boyett, James M. ; Wallace, Dana ; Gilbertson, Richard J. / Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96) : long-term results from a prospective, multicentre trial. In: Lancet Oncology. 2006 ; Vol. 7, No. 10. pp. 813-820.
@article{4759f8bc3fc34626a4bf32554384a482,
title = "Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial",
abstract = "Background: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. Methods: After resection, patients were classified as having average-risk medulloblastoma (≤1·5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma (>1·5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23·4 Gy for average-risk disease and 36·0-39·6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211. Findings: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89{\%}) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85{\%} (95{\%} CI 75-94) in patients in the average-risk group and 70{\%} (54-84) in those in the high-risk group (p=0·04); 5-year event-free survival was 83{\%} (73-93) and 70{\%} (55-85), respectively (p=0·046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0·04): 84{\%} (74-95) for classic histology, 77{\%} (49-100) for desmoplastic tumours, and 57{\%} (33-80) for large-cell anaplastic tumours. Interpretation: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.",
author = "Amar Gajjar and Murali Chintagumpala and David Ashley and Stewart Kellie and Kun, {Larry E.} and Merchant, {Thomas E.} and Shaio Woo and Greg Wheeler and Valerie Ahern and Krasin, {Matthew J.} and Maryam Fouladi and Alberto Broniscer and Robert Krance and Hale, {Gregory A.} and Stewart, {Clinton F.} and Robert Dauser and Sanford, {Robert A.} and Christine Fuller and Ching Lau and Boyett, {James M.} and Dana Wallace and Gilbertson, {Richard J.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/S1470-2045(06)70867-1",
language = "English (US)",
volume = "7",
pages = "813--820",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96)

T2 - long-term results from a prospective, multicentre trial

AU - Gajjar, Amar

AU - Chintagumpala, Murali

AU - Ashley, David

AU - Kellie, Stewart

AU - Kun, Larry E.

AU - Merchant, Thomas E.

AU - Woo, Shaio

AU - Wheeler, Greg

AU - Ahern, Valerie

AU - Krasin, Matthew J.

AU - Fouladi, Maryam

AU - Broniscer, Alberto

AU - Krance, Robert

AU - Hale, Gregory A.

AU - Stewart, Clinton F.

AU - Dauser, Robert

AU - Sanford, Robert A.

AU - Fuller, Christine

AU - Lau, Ching

AU - Boyett, James M.

AU - Wallace, Dana

AU - Gilbertson, Richard J.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. Methods: After resection, patients were classified as having average-risk medulloblastoma (≤1·5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma (>1·5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23·4 Gy for average-risk disease and 36·0-39·6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211. Findings: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89%) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85% (95% CI 75-94) in patients in the average-risk group and 70% (54-84) in those in the high-risk group (p=0·04); 5-year event-free survival was 83% (73-93) and 70% (55-85), respectively (p=0·046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0·04): 84% (74-95) for classic histology, 77% (49-100) for desmoplastic tumours, and 57% (33-80) for large-cell anaplastic tumours. Interpretation: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.

AB - Background: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. Methods: After resection, patients were classified as having average-risk medulloblastoma (≤1·5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma (>1·5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23·4 Gy for average-risk disease and 36·0-39·6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211. Findings: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89%) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85% (95% CI 75-94) in patients in the average-risk group and 70% (54-84) in those in the high-risk group (p=0·04); 5-year event-free survival was 83% (73-93) and 70% (55-85), respectively (p=0·046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0·04): 84% (74-95) for classic histology, 77% (49-100) for desmoplastic tumours, and 57% (33-80) for large-cell anaplastic tumours. Interpretation: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=33749044182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749044182&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(06)70867-1

DO - 10.1016/S1470-2045(06)70867-1

M3 - Article

C2 - 17012043

AN - SCOPUS:33749044182

VL - 7

SP - 813

EP - 820

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -